fda approves semaglutide for cardiovascular risk reduction Wegovy FDA approves Wegovy to reduce

Semaglutide constipation management and tirzepatide constipation treatment guides provide evidence-based strategies for addressing the most persistent GI side effect

The medications produce real, measurable weight loss, but the experience varies widely by patient

However, their unintended effect of suppressing appetite has made them a go-to choice for obesity management

Failure to watch what you eat and keep your sugar levels elevated may prevent you from seeing the intended results of the medication," she shares

GLP-2 acts on the gut itself, promoting intestinal growth and nutrient absorption, which is why its only drug treats short bowel syndrome